Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Opaleye Management Inc.

Q3 2023 · 13F-HR

Opaleye Management Inc.holdings as filed

Filed 2023-11-15 · accession 0001493152-23-041364

$307.4M
Reported value
40
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
415858109HROWHARROW HEALTH INC$54.5M17.7%3,795,000CommonSOLE
00445A100ACELYRIN INC$42.2M13.7%4,146,138CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$20.3M6.61%6,468,000CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$15.8M5.14%1,890,000CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$15.0M4.87%653,000CommonSOLE
14888U101CPRXCATALYST PHARMACEUTICALS INC$14.1M4.58%1,205,000CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$11.5M3.74%360,400CommonSOLE
G1110E107BHVNBIOHAVEN LTD$11.4M3.71%439,000CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS INC$11.0M3.58%370,000CommonSOLE
29772L108ETONETON PHARMACEUTICALS INC$10.1M3.30%2,430,270CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$8.4M2.73%311,500CommonSOLE
617760202MOR2MORPHOSYS AG$8.1M2.64%1,209,380CommonSOLE
872381108TELATELA BIO INC$6.0M1.95%750,000CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$5.0M1.63%875,405CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$4.8M1.57%500,000CommonSOLE
56854Q200MRNS*MARINUS PHARMACEUTICALS INC$4.7M1.53%584,000CommonSOLE
92243G108PCVXVAXCYTE INC$4.6M1.49%90,000CommonSOLE
74365U107TARAPROTARA THERAPEUTICS INC$4.5M1.46%2,692,594CommonSOLE
M96088105URGNUROGEN PHARMA LTD$4.5M1.46%320,000CommonSOLE
374163103GERNGERON CORP$4.1M1.32%1,915,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$4.0M1.29%4,754,200CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS INC$3.9M1.28%308,500CommonSOLE
98419J206XOMAXOMA CORP DEL$3.9M1.26%274,500CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$3.7M1.21%1,705,900CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$3.6M1.18%570,700CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$3.4M1.09%848,500CommonSOLE
B6S7WD106NYXHNYXOAH S A$3.1M1.01%441,896CommonSOLE
38341PAA0GOSS 5 06/01/27GOSSAMER BIO INC$3.1M1.01%8,000,000CommonSOLE
09075X108BRIDGEBIO PHARMA INC$3.0M0.99%455,573CommonSOLE
462260100IOVAIOVANCE BIOTHERAPEUTICS INC$2.8M0.90%610,000CommonSOLE
03828A101APLTAPPLIED THERAPEUTICS$2.2M0.72%893,000CommonSOLE
4495851081K0IGM BIOSCIIENCES INC$2.2M0.71%261,000CommonSOLE
192005106CDXSCODEXIS INC$2.1M0.69%1,118,900CommonSOLE
92337C203VSTMVERASTEM INC$1.7M0.56%211,400CommonSOLE
74017N105PGENPRECIGEN INC$1.3M0.43%928,500CommonSOLE
89237H209TRACON PHARMACEUTICALS INC$848,0820.28%4,764,508CommonSOLE
98422E103XERSXERIS BIOPHARMA HOLDINGS INC$725,4000.24%390,000CommonSOLE
34960Q109FORTRESS BIOTECH INC$580,6000.19%2,000,000CommonSOLE
49372L100KEZAR LIFE SCIENCES INC$505,7500.16%425,000CommonSOLE
75955J402RLMDRELMADA THERAPEUTICS INC$90,0000.03%30,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.